• 5597 Citations
  • 21 Scopus h-Index
20082020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

Orme, J. J., Jazieh, K. A., Xie, T., Harrington, S., Liu, X., Ball, M., Madden, B., Charlesworth, M. C., Azam, T. U., Lucien, F., Wootla, B., Li, Y., Villasboas, J. C., Mansfield, A. S., Dronca, R. S. & Dong, H., Jan 1 2020, In : OncoImmunology. 9, 1, 1744980.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

DeLeon, T. T., Almquist, D. R., Kipp, B. R., Langlais, B. T., Mangold, A., Winters, J. L., Kosiorek, H. E., Joseph, R. W., Dronca, R. S., Block, M. S., McWilliams, R. R., Kottschade, L. A., Rumilla, K. M., Voss, J. S., Seetharam, M., Sekulic, A., Markovic, S. N. & Bryce, A. H., 2020, In : PloS one. 15, 3, e0230306.

Research output: Contribution to journalArticle

Open Access

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Vera Aguilera, J., Paludo, J., McWilliams, R. R., Zhang, H., Li, Y., Kumar, A. B., Failing, J., Kottschade, L. A., Block, M. S., Markovic, S. N., Dong, H., Dronca, R. S. & Yan, Y., 2020, (Accepted/In press) In : Melanoma research. p. 364-375 12 p.

Research output: Contribution to journalArticle

Open Access

In Reply — Immune Checkpoint Inhibitor–Induced Type 1 Diabetes: An Underestimated Risk

Marin-Acevedo, J. A., Chirila, R. M. & Dronca, R., Mar 2020, In : Mayo Clinic proceedings. 95, 3, 1 p.

Research output: Contribution to journalLetter

Open Access
1 Scopus citations
2019

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

Failing, J. J., Dudek, O. A., Marin Acevedo, J. A., Chirila, R. M., Dong, H. M., Markovic, S. N. & Dronca, R. S., Aug 1 2019, In : Future Oncology. 15, 22, p. 2645-2656 12 p.

Research output: Contribution to journalReview article

1 Scopus citations

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine

Vera, J., Paludo, J., Kottschade, L., Brandt, J., Yan, Y., Block, M. S., Mc Williams, R. R., Dronca, R. S., Loprinzi, C. L., Grothey, A. F. & Markovic, S. N., Jan 1 2019, In : Supportive Care in Cancer.

Research output: Contribution to journalArticle

2 Scopus citations

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., Dronca, R., Mitchell, T. C., Patnaik, A., Zarour, H. M., Joshua, A. M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N. & Ribas, A., 2019, In : Annals of Oncology. 30, 4, p. 582-588 7 p., mdz011.

Research output: Contribution to journalArticle

Open Access
81 Scopus citations

Immune Checkpoint Inhibitor Toxicities

Marin-Acevedo, J. A., Chirila, R. M. & Dronca, R. S., Jul 1 2019, In : Mayo Clinic proceedings. 94, 7, p. 1321-1329 9 p.

Research output: Contribution to journalReview article

Open Access
8 Scopus citations

Paradox-driven adventures in the development of cancer immunology and immunotherapy

Barham, W., Gicobi, J. K., Yan, Y., Dronca, R. S. & Dong, H. M., Jan 1 2019, (Accepted/In press) In : Genes and Diseases.

Research output: Contribution to journalReview article

Open Access

Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT

Evans, J. D., Morris, L. K., Zhang, H., Cao, S., Liu, X., Mara, K. C., Stish, B. J., Davis, B. J., Mansfield, A., Dronca, R. S., Iott, M. J., Kwon, E. D., Foote, R. L., Olivier, K. R., Dong, H. M. & Park, S. S., Jan 1 2019, In : International Journal of Radiation Oncology Biology Physics. 103, 1, p. 229-240 12 p.

Research output: Contribution to journalArticle

1 Scopus citations

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

Duma, N., Abdel-Ghani, A., Yadav, S., Hoversten, K. P., Reed, C. T., Sitek, A. N., Enninga, E. A. L., Paludo, J., Aguilera, J. V., Leventakos, K., Lou, Y., Kottschade, L. A., Dong, H. M., Mansfield, A., Manochakian, R., Adjei, A. & Dronca, R. S., Jan 1 2019, In : Oncologist.

Research output: Contribution to journalArticle

10 Scopus citations
2018

Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P., Perrone, A., Zhang, J., Kang, S. P., Ebbinghaus, S. & 2 others, Anderson, K. M. & Gangadhar, T. C., Oct 15 2018, In : Clinical Cancer Research. 24, 20, p. 4960-4967 8 p.

Research output: Contribution to journalArticle

62 Scopus citations

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Yan, Y., Kumar, A. B., Finnes, H., Markovic, S. N., Park, S., Dronca, R. S. & Dong, H., 2018, In : Frontiers in immunology. 9, p. 1739 1 p., 1739.

Research output: Contribution to journalReview article

Open Access
42 Scopus citations

Contraction of T cell richness in lung cancer brain metastases

Mansfield, A., Ren, H., Sutor, S., Sarangi, V., Nair, A., Davila, J., Elsbernd, L. R., Udell, J. B., Dronca, R. S., Park, S. S., Markovic, S. N., Sun, Z. D., Halling, K. C., Nevala, W. K., Aubry, M. C., Dong, H. M. & Jen, J., Dec 1 2018, In : Scientific Reports. 8, 1, 2171.

Research output: Contribution to journalArticle

24 Scopus citations

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Stephen Hodi, F., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Peter Kang, S., Ebbinghaus, S. & 2 others, Anderson, K. M. & Gangadhar, T. C., Dec 1 2018, In : Clinical Cancer Research. 24, 23, 1 p.

Research output: Contribution to journalComment/debate

9 Scopus citations

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Yan, Y., Cao, S., Liu, X., Harrington, S. M., Bindeman, W. E., Adjei, A. A., Jang, J. S., Jen, J., Li, Y., Chanana, P., Mansfield, A. S., Park, S. S., Markovic, S. N., Dronca, R. S. & Dong, H., Apr 19 2018, In : JCI Insight. 3, 8

Research output: Contribution to journalArticle

Open Access
20 Scopus citations

Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma

Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., Dronca, R., Patnaik, A., Zarour, H., Kefford, R., Hersey, P., Zhang, J., Anderson, J., Diede, S. J., Ebbinghaus, S. & Hodi, F. S., Jun 10 2018, In : Journal of Clinical Oncology. 36, 17, p. 1668-1674 7 p.

Research output: Contribution to journalArticle

129 Scopus citations

Genitourinary malignancies

Dronca, R. & Kumar, A. B., Jan 5 2018, The Basics of Cancer Immunotherapy. Springer International Publishing, p. 79-94 16 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy

Duma, N., Azzouqa, A. G., Yadav, S., Hoversten, K., Reed, C., Sitek, A. N., Lou, Y., Molina, J., Halfdanarson, T., Leventakos, K., Joseph, R. W., Manochakian, R. & Dronca, R., Oct 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii432

Research output: Contribution to journalArticle

Open Access
2017

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma

Youland, R. S., Packard, A. T., Blanchard, M. J., Arnett, A. L., Wiseman, G. A., Kottschade, L. A., Dronca, R. S., Markovic, S. N., Olivier, K. R. & Park, S. S., Apr 1 2017, In : Advances in Radiation Oncology. 2, 2, p. 204-210 7 p.

Research output: Contribution to journalArticle

8 Scopus citations

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma

Leon-Ferre, R. A., Kottschade, L. A., Block, M. S., Mc Williams, R. R., Dronca, R. S., Creagan, E. T., Allred, J. B., Lowe, V. & Markovic, S. N., Mar 14 2017, (Accepted/In press) In : Melanoma Research.

Research output: Contribution to journalArticle

8 Scopus citations

Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients

Leontovich, A. A., Dronca, R. S., Nevala, W. K., Thompson, M. A., Kottschade, L. A., Ivanov, L. V. & Markovic, S. N., Jan 1 2017, In : Melanoma research. 27, 1, p. 32-42 11 p.

Research output: Contribution to journalArticle

8 Scopus citations

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Gangadhar, T. C., Hwu, W. J., Postow, M. A., Hamid, O., Daud, A., Dronca, R. S., Joseph, R. W., O'Day, S. J., Hodi, F. S., Pavlick, A. C., Kluger, H., Oxborough, R. P., Yang, A., Gazdoiu, M., Kush, D. A., Ebbinghaus, S. & Salama, A. K. S., 2017, In : Journal of Immunotherapy. 40, 9, p. 334-340 7 p.

Research output: Contribution to journalArticle

7 Scopus citations

Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy

Enninga, E. A. L., Harrington, S. M., Creedon, D. J., Ruano, R., Markovic, S. N., Dong, H. & Dronca, R. S., Jan 1 2017, (Accepted/In press) In : American Journal of Reproductive Immunology.

Research output: Contribution to journalArticle

21 Scopus citations

Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors — a major reason for enhanced chemosensitivity?

Shenoy, N., Dronca, R., Quevedo, F., Boorjian, S. A., Cheville, J., Costello, B., Kohli, M., Witzig, T. & Pagliaro, L., Aug 2017, In : Chinese Journal of Cancer Research. 29, 4, p. 374-378 5 p.

Research output: Contribution to journalArticle

3 Scopus citations

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab±everolimus for metastatic melanoma

Mc Williams, R. R., Allred, J. B., Slostad, J. A., Katipamula, R., Dronca, R. S., Rumilla, K. M., Erickson, L. A., Bryce, A. H., Joseph, R. W., Kottschade, L. A., King, D. M., Leitch, J. M. & Markovic, S. N., 2017, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

4 Scopus citations

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era

Youland, R. S., Blanchard, M. L., Dronca, R. S., Kottschade, L., Markovic, S. N., Olivier, K. R. & Park, S. S., Oct 1 2017, In : Clinical and Translational Radiation Oncology. 6, p. 25-30 6 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011

Enninga, E. A. L., Moser, J. C., Weaver, A. L., Markovic, S. N., Brewer, J. D., Leontovich, A. A., Hieken, T. J., Shuster, L., Kottschade, L. A., Olariu, A., Mansfield, A. & Dronca, R. S., 2017, (Accepted/In press) In : Cancer Medicine.

Research output: Contribution to journalArticle

19 Scopus citations

Whole blood mRNA expression-based prognosis of metastatic renal cell carcinoma

Giridhar, K. V., Sosa, C. P., Hillman, D. W., Sanhueza, C., Dalpiaz, C. L., Costello, B. A., Quevedo, F. J., Pitot, H. C., Dronca, R. S., Ertz, D., Cheville, J. C., Donkena, K. V. & Kohli, M., Nov 3 2017, In : International journal of molecular sciences. 18, 11, 2326.

Research output: Contribution to journalArticle

6 Scopus citations
2016

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B. & 8 others, Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P. & Robert, C., Apr 19 2016, In : JAMA - Journal of the American Medical Association. 315, 15, p. 1600-1609 10 p.

Research output: Contribution to journalArticle

488 Scopus citations

A T cell memory problem?

Dronca, R. S., Jan 20 2016, In : Science Translational Medicine. 8, 322, 322ec10.

Research output: Contribution to journalArticle

Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab

Hodi, F. S., Hwu, W. J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., Joshua, A. M., Hersey, P., Dronca, R., Joseph, R., Hille, D., Xue, D., Li, X. N., Kang, S. P., Ebbinghaus, S., Perrone, A. & 1 others, Wolchok, J. D., May 1 2016, In : Journal of Clinical Oncology. 34, 13, p. 1510-1517 8 p.

Research output: Contribution to journalArticle

368 Scopus citations

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W. J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., Joseph, R., Gangadhar, T. C., Dronca, R., Patnaik, A., Zarour, H., Roach, C., Toland, G., Lunceford, J. K., Li, X. N., Emancipator, K. & 4 others, Dolled-Filhart, M., Kang, S. P., Ebbinghaus, S. & Hamid, O., Dec 1 2016, In : Journal of Clinical Oncology. 34, 34, p. 4102-4109 8 p.

Research output: Contribution to journalArticle

252 Scopus citations
129 Scopus citations

The use of pembrolizumab for the treatment of metastatic uveal melanoma

Kottschade, L. A., McWilliams, R. R., Markovic, S. N., Block, M. S., Bisneto, J. V., Pham, A. Q., Esplin, B. L. & Dronca, R. S., Jan 1 2016, In : Melanoma research. 26, 3, p. 300-303 4 p.

Research output: Contribution to journalArticle

50 Scopus citations

Turning BiKEs into TriKEs to fight cancer

Dronca, R. S., Mar 2 2016, In : Science Translational Medicine. 8, 328, 328ec35.

Research output: Contribution to journalArticle

2015

A gender factor in shaping T-cell immunity to melanoma

Dronca, R. S. & Dong, H., 2015, In : Frontiers in Oncology. 5, FEB, 8.

Research output: Contribution to journalComment/debate

9 Scopus citations

Immunomodulatory antibody therapy of Cancer: The closer, the better

Dronca, R. S. & Dong, H., Mar 1 2015, In : Clinical Cancer Research. 21, 5, p. 944-946 3 p.

Research output: Contribution to journalArticle

7 Scopus citations

Immunotherapy: Fast and furious: Why all CARs are not made equal

Dronca, R. S., May 27 2015, In : Science Translational Medicine. 7, 289, 289ec86.

Research output: Contribution to journalArticle

It takes three to tango

Dronca, R. S., Sep 9 2015, In : Science Translational Medicine. 7, 304, 304ec153.

Research output: Contribution to journalArticle

Not just a fecal matter

Dronca, R. S., Dec 2 2015, In : Science Translational Medicine. 7, 316, 8023.

Research output: Contribution to journalArticle

27 Scopus citations

To beam or not to beam

Dronca, R. S., Oct 21 2015, In : Science Translational Medicine. 7, 310, 310ec179.

Research output: Contribution to journalArticle

When instability is a good thing

Dronca, R. S., Jun 17 2015, In : Science Translational Medicine. 7, 292, 292ec100.

Research output: Contribution to journalArticle

Why location is (still) everything

Dronca, R. S., Jul 29 2015, In : Science Translational Medicine. 7, 298, 298ec128.

Research output: Contribution to journalArticle

2014

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W. J., Gangadhar, T. C., Patnaik, A., Dronca, R., Zarour, H., Joseph, R. W., Boasberg, P., Chmielowski, B., Mateus, C., Postow, M. A., Gergich, K., Elassaiss-Schaap, J. & 5 others, Li, X. N., Iannone, R., Ebbinghaus, S. W., Kang, S. P. & Daud, A., Sep 20 2014, In : The Lancet. 384, 9948, p. 1109-1117 9 p.

Research output: Contribution to journalArticle

1142 Scopus citations
3 Scopus citations

Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients

Thompson, R. H., Boorjian, S. A., Kim, S. P., Cheville, J. C., Thapa, P., Tarrel, R., Dronca, R., Costello, B. & Frank, I., Jan 1 2014, In : BJU international. 113, 5 B, p. E17-E21

Research output: Contribution to journalArticle

33 Scopus citations

Immunomodulatory effects of sex hormones: Requirements for pregnancy and relevance in melanoma

Enninga, E. A. L., Holtan, S. G., Creedon, D. J., Dronca, R. S., Nevala, W. K., Ognjanovic, S. & Markovic, S. N., Apr 2014, In : Mayo Clinic proceedings. 89, 4, p. 520-535 16 p.

Research output: Contribution to journalReview article

29 Scopus citations